We are pleased that our new research on the role of TIGIT in #PancreaticCancer is highlighted in the current issue of Clinical Cancer Research.
Full article: aacrjournals.org/clincancerres/…
#Pancsm #Immunology #Oncology
Hochschulmedizin_TUD Nationales Centrum für Tumorerkrankungen Dresden VomLaborInDiePraxis

Day 2 #GI24 ASCO Highlights #CommunityOncology

1. #IMbrave151

2. GI/ColoRectal Ca in young adults

3. #ALPACA

4. #EXTEND

5. #NETTER2

6. #EMERALD1

#OncEd #MedEd #OncTwitter #MedTwitter #gism #crcsm #pancsm

1/7

Our case of a patient with #pancreaticcancer with MSI & BRAF fusion is now out in JCO Precision Oncology

ascopubs.org/doi/10.1200/PO…

👉BRAF fusion as an alternative route to MSI
👉excellent & long lasting response to #immunotherapy

OncoAlert 🚨 Ben Westphalen #PancSM 💜 #PrecisionMedicine

In my training was taught that 'KRAS is undruggable' but that's no longer true (and makes me increasingly inclined to look for actionable targets in PDAC in particular) #pancsm

nature.com/articles/s4159…

It was a pleasure and a privilege to write about new research, just out in Science Magazine, from dana_peer, Lowe Lab, Cassandra Burdziak & Direna Alonso-Curbelo that provides an in-depth analysis of the earliest beginnings of #PancreaticCancer . #pancsm
mskcc.org/news/expansion…

Less than 4 weeks to #ASCO23 - countdown is on
Great #GI lineup including #PROSPECT plenary
My list of #abstracts I will be watching for
#CRCsm #HPBCsm #STCsm #PANCsm
ASCO

📢 the updated ESMO - Eur. Oncology guidelines on #PancreaticCancer are out in Annals of Oncology

Everything you need to know including recommendations on #PrecisionMedicine 🎯🧬

OncoAlert 🚨 #pancsm

annalsofoncology.org/article/S0923-…

#OpenAccess #ResearchPaper in npj Journals #PrecisionOncology 👇🏼

Data from 3499 #PancreaticCancer samples shows distinct molecular & immune profiles in head vs. body/tail #cancers

#pancsm 💜 OncoAlert 🚨 Aatur Singhi, MD PhD KenOliveLab

nature.com/articles/s4169…

First randomized evidence supporting PFS benefit of MDT for OM-pancreatic cancer in P2-EXTEND trial. OS no different, but do other endpoints matter (e.g. maintenance of earlier line systemic therapy)? #GI24 #pancsm

Check out Dr. Richard Kim & Dr. Rutika Mehta Rutika Mehta Moffitt Cancer Center discussing a Year in Review: Upper GI Cancers

Full📽️on #VuMedi
👇
bit.ly/YIRupperGI

#CRCSM #gicsm #pancsm

Congrats to Adam Wolfe, MD, PhD, Tiantian Cui MD, PhD, and the rest of the stellar team for the Science Advances publication on nutrient scavenging in #pancreaticcancer . 👏
The work uncovers a pivotal role for caveolae-mediated endocytosis (CME) in fueling #PDAC growth. #pancsm #gism

Now live at #ASCO23 - Upper GI Poster discussion.

First data of the 3-Arm Arbeitsgemeinschaft Internistische Onkologie - AIO FOOTPATH trial in metastatic #pancsm presented by Ben Westphalen .

In FOOTPATH, sequential application of NAPOLI/FOLFOX was found to be effective and well tolerated.

OncoAlert 🚨

Eileen M O’Reilly dawn of #KRAS inh’s beyond #G12C , young onset #PDAC w/signal of KRAS WT, #KRAS WT #pancsm exquisitely targetable, & building on #POLO maintenance concept in #DDR #PancreaticCancer

Now at Cancer at Cedars-Sinai 4th Annual GI Tumor conf cedars.cloud-cme.com/gicancercme OncoAlert

Here is a little background on the POLO discussion for the casual browser. #PancSM

POLO is a mockery of science.

🔍 This #PancreaticCancerAwarenessMonth , let's shine a light on the need for increased awareness. Studies show smoking 🚭, alcohol consumption 🍷, and obesity 🍔 are potential risk factors. Let's spread knowledge and encourage preventive actions against pancreatic cancer. #pancsm

@laurenhenke presenting a brilliant talk on “state of the art” radiotherapy techniques and novel indications for PDAC 👏🏼👏🏼👏🏼

We’ve come a long way and looking forward to collaborations and future studies to help our patients in this tremendous area of need!
#ASCO23 #pancsm

Congrats Susan Tsai, MD, MHS (now Div Chief Surg Onc Ohio State Wexner Medical Center Surgery Dept.) & team MCW LaBahn Pancreatic Cancer Program for this publication in Gastroenterology! Findings have implications for molecularly selected trial design, biomarker discovery, & tailored therapeutics in #PancreaticCancer #pancsm

👍 Distinct molecular landscape of #YoungOnset #PancreaticCancer using Caris Life Sciences data from Jash Datta, MD ➡️ brnw.ch/21wFy6h #DattaLab Ifeanyichukwu Ogobuiro, MD, MHS #CARISPOA #pancsm

Dose modifications of gem/nab-pac were so common in this 2nd line #PDAC trial. For instance, in the 3rd cycle, 82% of remaining patients had a chemotherapy dose reduction (20/38) and/or schedule modification (22/38). #PancreaticCancer #Pancsm

jamanetwork.com/journals/jaman…

Pleasure to share our Johns Hopkins Kimmel Cancer Center results from an interception trial studying an off-the-shelf mutant KRAS vaccine in pts at high risk of developing PDAC at #AACR24 #pancsm